Somerset community hospital beds could close as trust reviews services
The number of inpatient beds at two community hospitals could be cut by a third if proposals go ahead. Somerset NHS Foundation Trust has confirmed it is in the "very early" stages of a consultation to reduce beds at Frome Community Hospital from 24 to 16, with a similar number of beds under threat at West Mendip Hospital in Glastonbury.The trust said it was looking at the "mix and balance" of its community services after an "increase" in people being cared for at home.However, MP for Frome and East Somerset Anna Sabine has set up a petition to stop what she described as "short-sighted" proposals, which she claimed could also see a number of job cuts.
Ms Sabine, who has launched the petition alongside councillor for Frome North Adam Boyden, claimed the closures were being proposed because too few patients were being discharged from Bath's Royal United Hospital (RUH) to Frome.But she said that when she toured the RUH - which is run by a different NHS authority to Frome - she was told their main problem is that they do not have suitable places to discharge patients into."We know the Royal United Hospitals struggle to discharge people and yet we're closing beds which would help this," she said.Ms Sabine said she is concerned that there is "a lack of joined up discussion" between Somerset NHS and the RUH.
'Well thought out plan'
However the MP for Glastonbury and Somerton, Sarah Dyke, whose constituency includes West Mendip Hospital, has given the proposals a cautious welcome.She said while she understood residents might be "concerned" at the planned bed closures, after an urgent meeting with the hospital trust's chief executive last week she believed the "overall direction of movement" was "the right one"."He has reassured me that this isn't a cost cutting exercise, but part of a well thought out strategic plan to shift reliance on community beds, moving the balance of care back to the home. But only when people are well enough to leave acute care within the hospital setting."She added that she understands "the funds and staff previously used for community hospital beds will be redeployed to make sure there are enough services in the community to facilitate this shift".
But Ms Sabine said while Somerset NHS Foundation Trust has promised more services at community hospitals across the county - this is not necessarily for Frome. "We suffer a little bit from being on the edge of Somerset and working with a hospital that is not in control by the same organisation and therefore we haven't had that guarantee," she said."It worries me that this is another example of Frome being short changed."She said the "short-sighted" approach to reduce beds in Frome did not take into account the difficulty people have getting to the RUH by public transport."Our hospitals don't need fewer beds, they need proper investment," she added.
Somerset NHS Foundation Trust told the BBC the proposal aims to "ensure" community care is offered "in the most appropriate setting".A spokesperson said there has been an increase in people receiving care at home in recent years as well as "significant investment" in services to support patients at home following an acute hospital admission."We are therefore looking at the range, mix and balance of NHS services that are provided in people's own homes, community hospital services and community hospital beds," they said."As a result, we are adjusting the number of beds that we are providing in some community hospitals to better match the demand, which includes a proposed reduction of eight beds at Frome Community Hospital, from 24 to 16."Alongside this, we are also looking at what other services we could provide in our community hospital settings, that are currently provided in the two main acute hospitals as we look to provide services more locally where it makes sense and is feasible to do so."Royal United Hospitals Bath NHS Foundation Trust has been approached for comment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
40 minutes ago
- Daily Mail
Subtle warning signs of 'silent disease' 16m Americans are living with and don't know
Nearly 16 million people have the most deadly type of liver disease, yet 80 percent of them have no idea. About five percent of adults worldwide have metabolic dysfunction-associated steatohepatitis (MASH) a serious liver condition caused by fat buildup, inflammation, and scarring. It's the most dangerous type of fatty liver disease MASH triggers liver scarring, which can progress to cirrhosis, and significantly increases the risk of heart disease, chronic kidney disease, and liver cancer. Just one in five Americans with the condition are actually diagnosed. Most patients do not experience symptoms until the damage is irreversible, making it a 'silent disease'. However, as the condition progresses, individuals may experience fatigue, pain or discomfort in the upper right belly, unexplained weight loss, weakness, and in some cases, jaundice (yellowing of the skin and eyes). A coalition of researchers from the US, Europe, and South Africa said that MASH-related liver failure and other complications, including deaths, are becoming more severe and common. The scientists behind the report, published in The Lancet Regional Health Europe, are calling for a doubling in MASH diagnosis rates from the 2022 level, about 13 percent (the current rate is just under 20 percent). They estimated that about 2.6 million people in the US, UK, Germany, and France have been diagnosed with MASH. But if testing were adequately improved and scaled up to become more accessible and commonplace, that figure could balloon to 6.1 million. People with type 2 diabetes, obesity, and heart disease should be prioritized for blood work and other screening tests, which will need to skyrocket from about two million to 36 million. Follow-up testing also needs to jump by nearly 1,300 percent to meet patient needs, and in more settings than liver clinics, such as family doctors' offices, and with diabetes and heart doctors. People with diabetes are especially prone to liver damage leading to MASH. Around 30 to 60 percent of diabetics also have MASH. Obesity is another leading risk factor, with estimates suggesting that 75 percent of overweight people and 90 percent with obesity will develop the condition. People with MASH also have a tripled risk of also developing heart disease, including coronary artery disease, stroke, and heart failure, compared to people without the condition. MASH diagnosis is poised for a major shift, mirroring past breakthroughs in chronic disease management. With new treatments approved and others on the horizon, the focus now turns to fixing systemic roadblocks. Currently, limited access to non-invasive tests and reliance on specialists leave most cases undetected until late stages. MASH arises from a cascade of liver damage typically linked to a buildup of fat in the liver, which triggers inflammation that damages liver cells and activates scar-forming cells. What was once healthy liver tissue becomes stiff, progressively crippling the liver's ability to detoxify blood. Though this is often painless until the damage becomes too severe to be reversed. If caught early, people can live normal lifespans with MASH. Lifestyle changes - eating a healthier diet, exercising regularly, and losing between five and 10 percent of one's body weight - can slow down the progression of MASH and repair some of the damage. Doctors may prescribe resmetirom, the first FDA-approved medication for MASH, to work hand-in-hand with those lifestyle changes. But severe damage can cause deadly conditions that cut a person's life drastically short. 'Each late-stage MASH diagnosis represents a missed opportunity for earlier intervention to prevent disease progression, threatening worse [liver] and [non-liver] outcomes for people living with the condition and greater costs for individuals, health systems, and societies,' researchers told a Barcelona medical conference this week. The solution requires concrete changes from moving diagnostics to implementing automated tools in electronic records. The researchers said that success in improving diagnostics goes beyond devising better tests. A fundamental reworking of methods of care is needed that catches at-risk patients before irreversible damage occurs. 'Paradigm shifts do not occur in a vacuum, but arise when leaps in science, technology, and innovation are coupled with changes in perception and understanding within a community,' they said. 'A confluence of factors in 2024 and expected drug approvals in many European countries in 2025 point to a near term tipping point for MASH diagnoses; nonetheless, focused and sustained efforts are needed to turn such opportunities into reality.'
BBC News
an hour ago
- BBC News
Stafford County Hospital opens new day-case surgery hub
A new £9.8m unit for day cases has officially opened at a hospital in Hospitals of North Midlands NHS Trust (UHNM) launched the unit at County Hospital in Stafford to tackle waiting list said it would offer thousands of patients quicker access to day-case unit has a dedicated space for patients who need colorectal, upper gastroenterology, orthopaedic or ear, nose and throat surgery, freeing up more space in main theatres. It follows the recent opening of the Staffordshire Treatment Suite and North Midlands Hand Centre, also both based at County hubs are part of NHS bosses' plans to increase surgical capacity and offer quicker access to some of the most common procedures. Bosses said the day-case unit was the latest stage in turning the hospital into an "elective-hub" for patients to be seen quicker at the site most suited to their unit has almost doubled capacity from the existing 15 beds on Ward 8 to 28."By further improving and extending our surgical facilities at County Hospital, we will be able to offer thousands of patients each year with quicker access to day-case surgery, helping to improve their quality of life whilst reducing waiting lists," said UHNM chief executive Dr Simon Constable. Follow BBC Stoke & Staffordshire on BBC Sounds, Facebook, X and Instagram.
The Sun
an hour ago
- The Sun
The ‘golden dose' of Mounjaro that experts warn could be deadly – as slimmers rave about it saving money
A GROWING number of slimmers are trying to squeeze extra jabs out of empty Mounjaro pens in a risky bid to cut costs. The weight-loss injections, which can cost hundreds of pounds a month, are designed to deliver a fixed weekly dose. But online users claim there's still a small amount of drug left after the final shot. They say it can be drawn out with a syringe for a bonus jab, dubbed the 'golden dose'. One TikTok user claimed the trick saved her a fortune. By getting five jabs from a four-dose pen, users reckon they can claw back £615 a year. The reports come after NHS England said only a small number of people will be able to get Mounjaro from their GP. It means most people will still have to pay for it privately - which can cost hundreds of pounds a month. 'The drugs are expensive but weight loss is strongly desired, so as a commodity, these drugs are hotly sought-after,' said Professor Naveed Sattar, a cardiologist and obesity expert at the University of Glasgow, said. 'It's no surprise people are going to such extraordinary lengths," she told the inews. Medics say the DIY hack is dangerous and could lead to infection, overdose or death. "People are reading these tips on online forums and being tempted to use them to save money," said Professor Penny Ward, a pharmaceutical expert at King's College London. Women taking fat jabs need 'effective contraception' - as health chiefs warn of serious harm to unborn babies "But they're risking serious side effects from overdosing by doing this - as well as the potential to develop a life-threatening infection. "The potential to develop a life-threatening infection. It's not a good idea at all," she told MailOnline. Talk of the so-called 'golden dose' is also spreading on Reddit weight-loss forums. In one thread with more than 50 comments, a user wrote: "After four pumps of your uk injection pen they tell you to throw it away. "But there is an extra dose or thereabouts in the pen you can self inject with an insulin needle." Another replied saying: "Known much more on here as the fifth dose." 2 Slimmers have also taken to TikTok to rave about the 'discovery'. In one video, a nurse demonstrates how to use a needle to extract leftover medicine from the pen. She wrote: "I do not condone or encourage anybody to take their golden dose this is just what I am doing." Huge risks Professor Penny warned that this practice can be dangerous for "several" reasons. "These injections contain a slight overfill to ensure the full recommended dose is delivered each time," she said. "But by drawing this out with a separate syringe and using it as a so-called fifth dose, you're exposing yourself to serious risk of infection.' Once the pen has been used, it's no longer sterile, meaning any leftover liquid could be contaminated with harmful bacteria. Injecting it could lead to abscesses or, in extreme cases, life-threatening sepsis. There's also the danger of taking too much. 'If you're using your own syringe, it's difficult to measure the correct amount - you may end up taking more than intended,' she warned. Overdosing on the jab can trigger nasty side effects like vomiting and diarrhoea, or in rare cases, pancreatitis - a serious and painful condition that may need hospital treatment. Around one in five cases result in serious complications, with up to 30 per cent proving fatal. The risk rises sharply with higher doses, as the drug can trigger digestive enzymes that begin attacking the pancreas itself. Symptoms include sudden, severe tummy pain, often spreading to the back, along with fever, nausea and a racing heartbeat. "The bigger the dose, the bigger the risk of pancreatitis," Professor Ward warned. Everything you need to know about fat jabs Weight loss jabs are all the rage as studies and patient stories reveal they help people shed flab at almost unbelievable rates, as well as appearing to reduce the risk of serious diseases. Wegovy – a modified version of type 2 diabetes drug Ozempic – and Mounjaro are the leading weight loss injections used in the UK. Wegovy, real name semaglutide, has been used on the NHS for years while Mounjaro (tirzepatide) is a newer and more powerful addition to the market. Mounjaro accounts for most private prescriptions for weight loss and is set to join Wegovy as an NHS staple this year. How do they work? The jabs work by suppressing your appetite, making you eat less so your body burns fat for energy instead and you lose weight. They do this my mimicking a hormone called GLP-1, which signals to the brain when the stomach is full, so the drugs are officially called GLP-1 receptor agonists. They slow down digestion and increase insulin production, lowering blood sugar, which is why they were first developed to treat type 2 diabetes in which patients' sugar levels are too high. Can I get them? NHS prescriptions of weight loss drugs, mainly Wegovy and an older version called Saxenda (chemical name liraglutide), are controlled through specialist weight loss clinics. Typically a patient will have to have a body mass index (BMI) of 30 or higher, classifying them as medically obese, and also have a weight-related health condition such as high blood pressure. GPs generally do not prescribe the drugs for weight loss. Private prescribers offer the jabs, most commonly Mounjaro, to anyone who is obese (BMI of 30+) or overweight (BMI 25-30) with a weight-related health risk. Private pharmacies have been rapped for handing them out too easily and video calls or face-to-face appointments are now mandatory to check a patient is being truthful about their size and health. Are there any risks? Yes – side effects are common but most are relatively mild. Around half of people taking the drug experience gut issues, including sickness, bloating, acid reflux, constipation and diarrhoea. Dr Sarah Jarvis, GP and clinical consultant at said: 'One of the more uncommon side effects is severe acute pancreatitis, which is extremely painful and happens to one in 500 people.' Other uncommon side effects include altered taste, kidney problems, allergic reactions, gallbladder problems and hypoglycemia. Evidence has so far been inconclusive about whether the injections are damaging to patients' mental health. Figures obtained by The Sun show that, up to January 2025, 85 patient deaths in the UK were suspected to be linked to the medicines. Mounjaro - dubbed the "King Kong" of weight loss jabs - works by mimicking hormones released by the body when you're full. This makes people feel fuller for longer and therefore less hungry. It appears to be to be more potent than Wegovy - another popular weight loss jab - causing about 20 per cent weight loss after a year's use, compared with Wegovy's 15 per cent. Mounjaro's active ingredient is tirzepatide, a lab-made compound that mimics two gut hormones - GLP-1 and GIP - which help control blood sugar and appetite. This is why it was initially approved to treat diabetes type 2, which happens when people can't control their blood sugar. But in December 2024, it was also cleared for use on the NHS for weight loss in people with a BMI of over 30, or over 27 plus one weight-related condition. 'Excess solution' should be 'discarded' If you notice there is a considerable amount of medication left in your pen after the last dose, Professor Penny added, it may mean that you're not using the injection properly. "Speak to your pharmacist about your technique, or check that you definitely have the right size syringe, as this can impact the amount of medication left over," she said. A spokesperson for Lilly - the drug's manufacturer - said users should not do this, as the remaining liquid may not be a full dose. 'It is important to note that there will be a residual amount of medicine left after the fourth dose," they said. "This does not correspond to a full dose." 'Any excess solution in the pen after use should be discarded.' Dr Alison Cave, chief safety officer of the Medicines and Healthcare products Regulatory Agency, added: "Medicines are approved according to strict dosage guidelines. "Failure to adhere with these guidelines, such as tampering with pre-dosed injection pens, could harm your health or cause personal injury. "People should follow the dosing directions provided by their healthcare provider when prescribed weight-loss medicines and use as directed in the patient information leaflet." What are the other side effects of weight loss jabs? Like any medication, weight loss jabs can have side effects. Common side effects of injections such as Ozempic include: Nausea: This is the most commonly reported side effect, especially when first starting the medication. It often decreases over time as your body adjusts. Vomiting: Can occur, often in conjunction with nausea. Diarrhea: Some people experience gastrointestinal upset. Constipation: Some individuals may also experience constipation. Stomach pain or discomfort: Some people may experience abdominal pain or discomfort. Reduced appetite: This is often a desired effect for people using Ozempic for weight loss. Indigestion: Can cause a feeling of bloating or discomfort after eating. Serious side effects can also include: Pancreatitis: In rare cases, Ozempic may increase the risk of inflammation of the pancreas, known as pancreatitis, which can cause severe stomach pain, nausea, and vomiting. Kidney problems: There have been reports of kidney issues, including kidney failure, though this is uncommon. Thyroid tumors: There's a potential increased risk of thyroid cancer, although this risk is based on animal studies. It is not confirmed in humans, but people with a history of thyroid cancer should avoid Ozempic. Vision problems: Rapid changes in blood sugar levels may affect vision, and some people have reported blurry vision when taking Ozempic. Hypoglycemia (low blood sugar): Especially if used with other medications like sulfonylureas or insulin.
